Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4784008
Max Phase: Preclinical
Molecular Formula: C39H60N4O8
Molecular Weight: 712.93
Molecule Type: Unknown
Associated Items:
ID: ALA4784008
Max Phase: Preclinical
Molecular Formula: C39H60N4O8
Molecular Weight: 712.93
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C#CCOC(=O)[C@@H](NC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)C12CC3CC(CC(C3)C1)C2)C(C)C
Standard InChI: InChI=1S/C39H60N4O8/c1-9-15-50-36(48)32(24(4)5)42-33(45)28(12-13-31(44)51-38(6,7)8)40-34(46)29(16-23(2)3)41-35(47)30-11-10-14-43(30)37(49)39-20-25-17-26(21-39)19-27(18-25)22-39/h1,23-30,32H,10-22H2,2-8H3,(H,40,46)(H,41,47)(H,42,45)/t25?,26?,27?,28-,29-,30-,32-,39?/m0/s1
Standard InChI Key: SGKSDONDRFMHDB-SCDBPOTISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 712.93 | Molecular Weight (Monoisotopic): 712.4411 | AlogP: 3.65 | #Rotatable Bonds: 15 |
Polar Surface Area: 160.21 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 12 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.82 | CX Basic pKa: 1.01 | CX LogP: 3.87 | CX LogD: 3.87 |
Aromatic Rings: 0 | Heavy Atoms: 51 | QED Weighted: 0.17 | Np Likeness Score: -0.47 |
1. Wang P,Wadsworth PA,Dvorak NM,Singh AK,Chen H,Liu Z,Zhou R,Holthauzen LMF,Zhou J,Laezza F. (2020) Design, Synthesis, and Pharmacological Evaluation of Analogues Derived from the PLEV Tetrapeptide as Protein-Protein Interaction Modulators of Voltage-Gated Sodium Channel 1.6., 63 (20): [PMID:33054193] [10.1021/acs.jmedchem.0c00531] |
Source(1):